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Abstract
Members of the human KIR class I MHC receptor gene family contain multiple promoters that 
determine the variegated expression of KIR on NK cells. In order to identify novel genetic 
alterations associated with decreased KIR expression, a group of donors was characterized for KIR 
gene content, transcripts, and protein expression. An individual with a single copy of the KIR2DL1 
gene but a very low level of gene expression was identified. The low expression phenotype was 
associated with a SNP that created a binding site for the inhibitory ZEB1 transcription factor 
adjacent to a c-Myc binding site previously implicated in distal promoter activity. Individuals 
possessing this SNP had a substantial decrease in distal KIR2DL1 transcripts initiating from a 
novel intermediate promoter located 230 bp upstream of the proximal promoter start site. 
Surprisingly, there was no decrease in transcription from the KIR2DL1 proximal promoter. 
Reduced intermediate promoter activity revealed the existence of alternatively spliced KIR2DL1 
transcripts containing premature termination codons that initiated from the proximal KIR2DL1 
promoter. Altogether, these results indicate that distal transcripts are necessary for KIR2DL1 
protein expression and are required for proper processing of sense transcripts from the 
bidirectional proximal promoter.
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Introduction
Natural Killer (NK) cells are lymphocytes of the innate immune system that play an 
important role in the elimination of neoplastic or virus-infected cells1. NK cell cytotoxic 
activity is controlled in part by cell surface receptors for class I MHC that survey potential 
target cells for aberrant class I expression2. Human NK cells use the killer cell 
immunoglobulin-like receptor (KIR) family3 to interrogate class I status, whereas murine 
NK cells use members of the C-type lectin-related Ly49 family4, 5. KIR and Ly49 genes are 
expressed in a probabilistic fashion, generating subsets of NK cells with distinct class I 
MHC recognition properties6, 7. The selectively expressed human KIR gene family provides 
an interesting model system for the study of stochastic activation of gene expression. The 
proximal promoter of most KIR genes is kept in a silent state by promoter methylation8, 9. 
An AML/RUNX transcription factor binding site in the proximal promoter region has been 
suggested to play a role in the demethylation of the proximal promoter, since loss of this site 
in the non-transcribed KIR2DL5*002 allele is associated with non-expression, even though 
loss of the AML/RUNX site does not abrogate proximal promoter activity in luciferase 
reporter assays10, 11. Furthermore, treatment of NK cells with the demethylating agent 5-
azacytidine, leads to KIR2DL5*002 transcription, supporting a role for AML/RUNX in 
catalyzing promoter demethylation. Studies of a distal KIR promoter have indicated a role 
for distal transcripts in gene activation, since distal transcription precedes gene expression, 
and increased distal transcripts are associated with a higher frequency of gene 
expression12, 13. A c-Myc binding site in the distal promoter was shown to be important for 
promoter activity, and over-expression of c-Myc in developing NK cells led to increased 
distal transcript levels and an increased frequency of NK cells expressing KIR. A model of 
KIR gene activation has been proposed in which the distal promoter generates transcripts 
that traverse the proximal promoter region, leading to an opening of this region and allowing 
access of key transcription factors involved in promoter demethylation, such as AML/
RUNX14.
The variegated expression of Ly49 genes is controlled by a bidirectional promoter that acts 
as a probabilistic switch15. The generation of forward transcripts from this upstream element 
(Pro1) in immature NK cells leads to activation of the downstream proximal promoter. The 
expression of a Ly49 gene from the proximal promoter is dependent on distal transcription, 
since Pro1 deletion eliminates Ly49 transcription16. The probabilistic activation of KIR 
genes has been linked to the bi-directional nature of the KIR proximal promoter17. Variation 
in the relative strength of transcription factor binding sites that promote either sense or 
antisense transcription from the proximal promoter in specific KIR genes or alleles results in 
bi-directional promoters with differing probabilities of generating a forward transcript18. 
KIR genes or alleles with a high ratio of sense to antisense proximal promoter activity are 
expressed by a greater percentage of NK cells than KIR with a low sense to antisense ratio. 
The KIR antisense transcript has been associated with the production of a 28 base piwi-RNA 
that may lead to re-silencing of KIR loci that produce the antisense transcript19. Although 
numerous KIR alleles have been identified that are non-expressed due to the presence of 
stop codons in the coding region, only one gene (KIR2DL5)10 has been identified that 
contains non-transcribed alleles. In the current study, we sought to determine if there were 
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additional non-transcribed KIR alleles, to obtain further information with regard to the 
genomic regions controlling gene expression.
Results
Identification of a weakly expressed KIR2DL1 allele
In order to identify novel genetic alterations associated with a lack of KIR transcription, 
healthy donors were screened for individuals that possessed but did not show significant 
expression of KIR genes. A group of 182 National Marrow Donor Program (NMDP) donors 
were characterized for KIR gene transcription by qRT-PCR, KIR gene content, and FACS 
analysis of KIR surface expression. An individual was discovered that possessed the 
KIR2DL1 gene but had barely detectable gene expression by either FACS or qRT-PCR 
(Figure 1).
Identification of SNPs specific to the poorly expressed KIR2DL1 allele
Complete sequencing of the KIR2DL1 gene from the individual with low KIR2DL1 
expression revealed the presence of a single allele containing an intact coding region. 
Analysis of the three known promoter regions as well as the complete 2 kb intergenic region 
preceding the first exon revealed a cluster of 3 single nucleotide polymorphisms (SNPs) in 
the distal promoter region approximately 1 kb upstream from the start of KIR2DL1 
translation (Figure 2). These 3 SNPs, together with the presence of an exon 4 segment 
derived from the KIR2DL1*002 allele constituted the only sequence differences between the 
KIR2DL1 gene in this donor and the previously reported complete sequence of a 
KIR2DL1*00401 allele (GenBank accession GU182347). The 3 SNPs present in the novel 
KIR2DL1 allele match the sequence normally found in the distal promoter region of the non-
transcribed KIR2DL5*002 allele as well as the KIR3DP1 pseudogene (Figure 2). However, 
the well-characterized KIR2DL5*002 SNP that disrupts the proximal promoter AML/RUNX 
site was not present, indicating that the distal promoter variant was able to inhibit KIR 
expression by a novel mechanism. This also raises the possibility that the KIR2DL1 SNPs 
identified here could be involved in the silencing of KIR2DL5*002.
The KIR2DL1 distal SNP creates a ZEB1 binding site
Examination of the distal SNPs associated with non-expression of KIR2DL1 revealed that 
the SNP at position -1206 created a binding site for the Zinc finger E-box-binding 
homeobox 1 (ZEB1) protein, a transcription factor that has been shown to inhibit IL2 gene 
expression20. ZEB1 requires two E-box motifs (CACCT) for efficient binding to DNA21, 
and the polymorphism generates a second E-box motif in close proximity to an E-box motif 
adjacent to the c-Myc/USF binding site (Figure 2) that has been previously implicated in the 
activation of KIR genes13. EMSA analysis indicated that ZEB1 binds to the E-box pair 
composed of the novel E-box generated by the polymorphism and the site located next to the 
c-Myc site (Figure 3). The generation of this novel ZEB1-binding site adjacent to the Myc 
site shown to enhance distal transcription suggested that the presence of the ZEB1 SNP 
might decrease activity of the KIR2DL1 distal promoter, reducing the probability of 
proximal promoter activation. Interestingly, all known KIR2DL5 alleles contain the SNP that 
generates the ZEB1-binding site, which may account for the low frequency of expression 
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observed for KIR2DL5A*00122. Some KIR2DP1 alleles also contain this SNP, however the 
complete absence of KIR2DP1 transcripts precludes any observable effect of the ZEB1 SNP 
on the transcription of this gene.
Association of the ZEB1 SNP with decreased KIR2DL1 expression
PCR screening of archived DNA from an additional 376 donors from the NCI Frederick 
Research Donor Program, resulted in the identification of 6 additional individuals (1.6 %) 
possessing the ZEB1-associated SNP in KIR2DL1, all of which were associated with a 
KIR2DL1*004 allele. The complete sequence of the novel KIR2DL1 allele can be found in 
GenBank under accession number KJ913660. Interestingly, none of these donors had the 
accompanying substitution of a KIR2DL1*002-like exon 4 found in the original KIR2DL1 
low-expression variant. Three individuals with the novel SNP were available for additional 
characterization, and they were evaluated for cell surface expression of KIR2DL1 as 
compared to normal donors that possessed either 0, 1, or 2 copies of the wild-type KIR2DL1 
gene. FACS analysis of these donors demonstrated low KIR2DL1 surface expression (2.6% 
of NK cells) in a donor containing a single copy of the mutated KIR2DL1 gene, confirming 
an association of the ZEB1 SNP with poor expression (Figure 4). The presence of both wild-
type and mutant KIR2DL1 alleles produced normal levels of KIR2DL1 expression, 
indicating the absence of any trans effects of the ZEB1 SNP. The observed higher than 
expected frequency of KIR2DL1 expression (25.8%) in the individual with only one wild-
type allele can be accounted for by the presence of KIR2DS5, as the anti-KIR2DL1 antibody 
used for detection has been shown to also recognize KIR2DS523. The KIR2DS5 gene was 
not present in any of the other donors tested. In addition, analysis of an individual 
possessing a mutant copy of KIR2DL1 together with the KIR2DS3 gene revealed moderate 
low intensity expression (11.1%), suggesting weak cross-reactivity of the anti-KIR2DL1 
antibody with KIR2DS3 in this individual.
The ZEB1 SNP decreases distal transcripts
In order to determine if the ZEB1 SNP affected distal promoter activity, RT-PCR was 
performed with primers specific for the KIR2DL1 distal transcript. As shown in Figure 5a, 
there was a substantial reduction in distal transcription in individuals possessing the ZEB1-
associated SNP, consistent with an inhibitory effect of ZEB1 binding in the upstream region.
Surprisingly, analysis of proximal promoter transcripts showed no decrease in the level of 
proximal KIR2DL1 promoter activity (Figure 5b), even in an individual that possessed only 
a single copy of the KIR2DL1 gene containing the ZEB1 SNP. The proximal transcript 
levels actually increased in the ZEB1 mutant, possibly due to the loss of competition from 
the upstream promoter. Furthermore, the levels of distal transcript paralleled the level of 
protein expression observed in Figure 4, whereas proximal transcript did not. Since previous 
studies had demonstrated distal KIR transcripts initiating approximately 800 bp upstream of 
the KIR start codon were not translatable, 5’ RACE was performed with primers just 
upstream of the proximal promoter to look for additional distal transcription start sites. Two 
novel distal transcript start sites 230 and 273 nucleotides upstream from the major proximal 
promoter start site were identified in RNA from individuals with wild type KIR2DL1 alleles, 
indicating the presence of an intermediate promoter (Figure 5c). The lack of correlation 
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between proximal promoter activity and protein expression suggests that transcripts initiated 
from the novel intermediate promoter may be responsible for KIR2DL1 expression by 
mature NK cells. To investigate whether or not these novel transcripts are capable of 
expressing protein, a full-length cDNA originating from the intermediate promoter 
(GenBank accession number KJ699235) was cloned into an expression vector and 
transfected into the human 239T cell line. Expression of KIR2DL1 from the intermediate 
transcript was comparable to expression from the proximal transcript, indicating that the 
additional 230 base 5’ untranslated region of the intermediate transcript did not inhibit 
expression, consistent with the association of the novel promoter with KIR expression by 
mature NK cells. A KIR3DL1 cDNA originating from the intermediate promoter was also 
tested and found to be capable of producing KIR3DL1 expression (data not shown).
Proximal KIR2DL1 transcripts contain alternative exons
The lack of correlation between KIR2DL1 expression and proximal transcription was 
perplexing, since the major start site of KIR2DL1 transcription in NK cells has been mapped 
to the proximal promoter12, 24, 25. However, RT-PCR analysis of individuals with reduced 
KIR2DL1 distal transcript revealed the presence of two alternative exons containing stop 
codons (Figure 6), suggesting that proximal promoter transcripts might be alternatively 
spliced and potentially incapable of producing translatable KIR2DL1 mRNA.
To further investigate this possibility, qRT-PCR was performed with antisense primers 
specific for the alternate exons together with forward primers from either the intermediate or 
proximal transcripts. Efficient amplification of alternative exon-containing transcripts was 
only observed with the forward primer from the proximal transcript, suggesting that the 
alternative exons are specific to the proximal transcript (Figure 6c). However, the alternative 
exon-containing transcripts were not as abundant in NK cells that contained only wild-type 
KIR2DL1 genes, suggesting that the presence of distal transcript either inhibits alternative 
splicing or ZEB1 binding to the distal promoter region affects alternative splicing of the 
proximal transcript. 5’ RACE performed using primers from the alternative exons generated 
5’ ends mapping to the proximal promoter region. No start sites upstream of the proximal 
promoter were detected with alternative exon primers (data not shown).
Discussion
Studies of the Pro1 distal bidirectional promoter present in the murine Ly49 genes have 
indicated that forward transcription from the distal promoter is required for activation of the 
proximal Ly49 promoter (Pro2) that is responsible for Ly49 expression in mature NK cells. 
This was demonstrated by both naturally occurring deletions of the distal promoter as well 
as a direct deletion of the Pro1 element in Ly49a transgenic mice26. The distal KIR promoter 
has been shown to be transcriptionally active in NK precursors that lack KIR expression, 
suggesting that it may also play a role in the initial opening of the proximal KIR promoter 
analogous to the murine Ly49 Pro1 promoter13. The weakly expressed KIR2DL1 allele 
reported herein has revealed the presence of a novel KIR intermediate promoter 230 bp 
upstream of the proximal promoter, and transcription from this novel promoter is associated 
with protein expression. For the purposes of this discussion, we will refer to this new 
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intermediate promoter as Pro-I. The bi-directional proximal promoter will be referred to as 
the probabilistic switch, or Pro-S. The previously described distal promoter will be referred 
to as Pro-D. The presence of a ZEB1 binding site in Pro-D was correlated with a low level 
of KIR2DL1 distal transcription in several individuals. The ZEB1 SNP was also associated 
with decreased in vitro KIR2DL1 Pro-I activity (data not shown) and decreased Pro-I 
transcripts in NK cells, indicating an enhancer function of the Pro-D element for Pro-I 
transcription. Pro-S activity was unchanged, indicating an association of Pro-I transcription 
with KIR2DL1 protein expression. The results obtained in this study necessitate a revision 
of the model of probabilistic KIR gene activation. The previous observation that CD56dim, 
KIR-ve NK cells contain antisense transcripts from Pro-S indicated that these cells 
represented the phase of NK development where the probabilistic Pro-S element was active, 
however these cells also contain forward Pro-S transcripts, but no KIR protein expression. 
The discovery of a novel promoter associated with KIR expression indicates that Pro-S 
transcription alone is not sufficient for protein expression, and it is Pro-I that drives 
expression in mature NK cells either directly, or by facilitating proper splicing of proximal 
transcripts. This also reveals another parallel with the murine Ly49 system: forward 
transcripts from bidirectional promoters active in immature NK cells are non-translatable. 
Therefore, the process of KIR gene activation should proceed through three stages as 
defined by the activity of the Pro-D, Pro-S, and Pro-I elements (Figure 7). NK precursors 
have an active Pro-D element that is associated with the activation of the Pro-S region in 
developing NK cells. NK cells undergoing the CD56bright to CD56dim transition represent 
the probabilistic transcription phase marked by Pro-S activity and the presence of either 
antisense transcripts or forward non-translatable transcript. Mature KIR-positive NK cells 
should exhibit Pro-I activity driving the expression of KIR protein or preventing alternative 
splicing of proximal transcripts. The inability of previous studies of KIR transcript initiation 
sites to detect Pro-I transcripts may be due to a high concentration of proximal Pro-S 
transcripts masking the presence of upstream start sites. The PCR and subsequent cloning 
steps performed in 5’-RACE create a bias toward smaller products, making it difficult to 
identify start sites that are further upstream. There is also a bias toward more abundant 
transcripts, and Pro-S transcripts are approximately 5-fold higher than the Pro-I transcripts 
detected in purified peripheral NK cell populations12. As a result, the Pro-I transcription 
start site could only be mapped by 5’ RACE using primers upstream of the Pro-S start site.
The proposed ability of Pro-I to drive KIR protein expression in mature NK cells and the 
non-translatable Pro-S transcripts associated with low Pro-I activity suggests that SNPs 
affecting the level of KIR expression should map to the Pro-I element and the upstream 
enhancer Pro-D as described in this study, whereas SNPs affecting the percentage of NK 
cells expressing a given KIR should map to the Pro-S element, as previously demonstrated 
for the KIR3DL1 gene18. To test the prediction that Pro-I SNPs might affect the intensity of 
KIR3DL1 expression, the KIR3DL1 Pro-I region was compared amongst the KIR3DL1 
alleles represented in GenBank. A single bp deletion was found in the KIR3DL1*005 and 
KIR3DL1*004 alleles but not in any of the other KIR3DL1 alleles or KIR3DS1. This deletion 
affects a consensus AP-1 transcription factor binding site, and would be predicted to result 
in decreased Pro-I promoter activity, consistent with the reported low expression phenotype 
of KIR3DL1*005.
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The analysis of a KIR2DL1 allele associated with low expression revealed a novel KIR 
variant, but in addition, has resulted in a significant change in our understanding of KIR 
gene regulation. The promoter previously considered to be responsible for KIR protein 
expression (Pro-S), may function primarily as a probabilistic switch that governs the 
frequency of gene activation in developing NK cells. This novel paradigm of KIR gene 
regulation necessitates a shift away from analysis of the proximal KIR promoter when 
considering polymorphisms that affect the intensity of KIR expression. Mature NK cells 
require KIR2DL1 Pro-I transcripts to express the protein, Pro-I transcripts have been 
identified for the KIR3DL1 gene (data not shown), and the Pro-I element is conserved 
among all KIR genes except for KIR3DL3, a gene that is not expressed by mature circulating 
NK cells. This suggests that most KIR genes use Pro-I for the expression of KIR protein in 
mature NK cells. Of particular interest is the divergence of the KIR2DL3/2DL2/2DS2 Pro-I 
elements that only share 84% homology with the 3’ half of the KIR2DL1 Pro-I element and 
possess no significant homology within the 5’ half of the promoter. This may explain the 
previous observation that NK cells derived from hematopoietic progenitor cells generally 
acquire the C1-specific inhibitory KIR2DL2/3 receptors at earlier time points than the C2-
specific KIR2DL127. Comparison of Pro-S elements of the KIR genes has revealed 5 
KIR2DL2/3-specific SNPs, however there is no significant difference in KIR2DL2/3 Pro-S 
activity as compared to KIR3DL1*002 Pro-S activity18, 28. It will therefore be of interest to 
compare Pro-I transcripts and Pro-I activity of these genes to see if a correlation exists 
between divergent Pro-I structures and distinct expression patterns.
In conclusion, the discovery of a novel KIR promoter associated with protein expression by 
mature NK cells mandates a re-examination of previous data correlating proximal promoter 
polymorphisms with differences in the timing, tissue specificity, or level of transcription of 
individual KIR genes or alleles. This paradigm shift promises to provide insight into gene/
allele-specific differences that have not been adequately explained by study of the proximal 
KIR promoter.
Materials and methods
Cell lines
YT cells were cultured in RPMI 1640 media containing 10% fetal bovine serum (FBS), 100 
U/ml penicillin, 100 U/ml streptomycin, sodium pyruvate, and L-glutamine. HEK293T cells 
were cultured in Dulbecco’s modified Eagle medium (DMEM) containing 10% fetal bovine 
serum (FBS), 100 U/ml penicillin, 100 U/ml streptomycin (P/S), sodium pyruvate, and L-
glutamine.
Donors and NK Cell Isolation
Collection of DNA and blood samples from 162 donor/recipient pairs from unrelated donor 
hematopoietic cell transplants performed to treat AML was facilitated by the National 
Marrow Donor Program (NMDP, Minneapolis, MN) Research Sample Repository. Samples 
were collected after informed consent and approval from the NMDP and University of 
Minnesota Institutional Review Boards were obtained in accordance with the Declaration of 
Helsinki. Healthy volunteers were recruited through the NCI-Frederick Research Donor 
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Program (http://www.ncifcrf.gov/rdp/). The KIR genotype of each donor was determined as 
previously described29. NK cells were separated from the peripheral blood of healthy donors 
by Histopaque® (Sigma-Aldrich, Saint Louis, MO, USA) gradient centrifugation using the 
RosetteSep™ Human NK Cell Enrichment Cocktail (STEMCELL Technologies, Vancouver 
BC, CA).
Flow Cytometric Analysis of KIR Expression on Peripheral Blood NK Cells
The proportion of NK cells expressing KIR2DL1 was assessed in whole blood by three-
color flow cytometry. NK cells were identified using anti-human CD56-APC (Beckman 
Coulter, Pasadena, CA, USA). T cells were labeled with anti-human CD3-Pacific Blue 
(eBioscience, San Diego, CA, USA). KIR2DL1 expressing cells were identified with the 
clone 143211-FITC KIR2DL1-specific antibody (R&D Systems, Minneapolis, MN, USA). 
Briefly, 200 µl of EDTA-treated blood was incubated with a cocktail of the 3 mAbs for 30 
min on ice. Erythrocytes were lysed by the addition of 3 ml of RBC lysis buffer (150 mM 
NH4Cl, 10 mM NaHCO3, 1 mM EDTA, pH 7.4), and the remaining cells were analyzed 
with a FACSort flow cytometer (Becton & Dickinson, San Jose, CA). Events (25,000) were 
collected in the lymphocyte gate and analyzed. The percentage of CD3-CD56+ NK cells 
expressing KIR2DL1 was determined.
PCR screening and sequencing of KIR2DL1 genes
PCR screening of donors for the ZEB1 SNP was performed with a KIR2DL1-specific 
forward primer (5’-GGGTTTACAGTTCTTTATTGAACCG-3’) together with a reverse 
primer recognizing the KIR3DP1/KIR2DL5B sequence found in the low expresser variant 
(5’-CTCAATAAATAATATTAAACCAATTGGTTAC-3’). To obtain the complete 
sequence of the KIR2DL1 alleles present in each donor, 50 ng of leukocyte DNA obtained 
from donor blood was subjected to PCR with a series of KIR2DL1/S1-specific primers to 
produce overlapping ~ 1 kb amplicons spanning the complete gene from the polyA site of 
the preceding KIR2DP1 gene to the polyA site of KIR2DL1. PCR fragments were cloned 
into the pCR2.1-topo vector (Invitrogen, Carlsbad, CA, USA). A minimum of six clones of 
each fragment was sequenced for each KIR2DL1/S1 allele present.
RT-PCR of KIR transcripts
Total RNA was purified from 1×107 donor NK cells with the RNeasy kit (Qiagen, Valencia, 
CA, USA) and cDNA synthesis was carried out using Random Hexamer primer, Taqman 
Reverse Transcription Reagents kit (Applied Biosystems Foster City, CA, USA) according 
to the manufacturer's instructions. The initial screening of donors for transcripts of all 
transcribed KIR genes was performed using primer sets previously described30. The primers 
used in the KIR2DL1-specific qRT-PCR assay were: KIR2DL1-Distal forward primer (5’-
CTCGTGTTCGGGAGGTTGGATCTC-3’); KIR2DL1-Proximal forward primer (5’-
GTCGCGGCTGCCTGTCTGCTC-3’); KIR2DL1-Exon 3 reverse primer (5’-
CTCTCTGTGCAGAAGGAAGTGTT-3’); KIR2DL1-AltExon B reverse primer (5’-
CCAGCCTCTATAGGCCACCTGC-3’); Actin-beta forward primer (5’-
CCTGGCACCCAGCACAAT-3’); Actin-beta reverse primer (5’- 
GGGCCGGACTCGTCATACT-3’). Reactions were carried out using FastStart SYBR 
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Green Master kit (Roche Diagnostics, Indianapolis, IN, USA) on the 7300 Real-Time PCR 
System (Applied Biosystems). The qRT-PCR was performed in duplicate and was repeated 
in at least three separate experiments using the following conditions. Reaction mixtures 
contained 12.5 µl of SYBR Green master mix, 2 pmoles each of forward and reverse 
primers, and 10ng cDNA. Thermocycler conditions included initial denaturation at 50°C and 
95°C (10 min each), followed by 40 cycles at 95°C (15 s) and 60°C (1 min). Melting curve 
analyses were performed to verify the amplification specificity. Relative quantification of 
gene expression was performed according to the ΔΔ-CT method using StepOne Software 2.0 
(Applied Biosystems). All PCR products were cloned into pCR2.1-topo (Invitrogen) and 
sequenced in order to verify the identity of the transcript and the KIR gene responsible for 
the product.
RNA Ligase Mediated 5’ RACE Analysis of KIR2DL1 Transcripts
5’ RACE was performed on human donor NK cell RNA using the FirstChoice® RLM-
RACE kit (Ambion Inc, Austin, TX, USA). KIR2DL1 gene-specific cDNA was generated 
using a KIR2DL1 Exon 3 reverse primer: 5’-
CAATGAGGCGCAAAGTGTCGTTAAAC-3’. First round PCR amplification was 
performed using the 5’ outer adapter and the KIR2DL1-Exon 3 reverse primer 5’-
CTCTCTGTGCAGAAGGAAGTGTT-3’ at an annealing temperature of 59° C for 35 cycles 
with Platinum PCR Supermix (Invitrogen). Excess primers from first round PCR reactions 
were removed with the Charge-Switch PCR Clean-Up Kit (Invitrogen). Nested PCR was 
subsequently performed with the 5’ inner adapter primer and the KIR2DL1-Alternate exon 2 
reverse primer (5’-CCAGCCTCTATAGGCCACCTGC-3’) or a reverse primer upstream of 
the proximal promoter start sites (5’-TAGTGTCCTTCACTATGACCAAC-3’) at an 
annealing temperature of 60° C for 30 cycles. PCR products were cloned into pCR2.1 Topo 
(Invitrogen) and sequences analyzed to map the 5’ start sites.
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared from YT cells using the CellLytic NuCLEAR extraction kit 
(Sigma-Aldrich). Protein concentration was measured with a Bio-Rad protein assay 
(Hercules, CA), and samples were stored at −70°C until use. Double-stranded DNA 
oligonucleotide probes corresponding to the predicted ZEB1 binding sequence of the mutant 
KIR2DL1 distal promoter (TTCCTAGGTGTAACCAATTGGTTTAATA-
TTATTTATTGAGAAGACATTCTATGCCACCTTAAACCACACGGCAG) or the wild-
type sequence were synthesized. Probes were labeled with [α-32P]deoxycytidine 
triphosphate (3000 Ci/mmol; PerkinElmer Life and Analytical Sciences, Waltham, MA) by 
fill-in using the Klenow fragment of DNA polymerase I (Invitrogen). 32P-labeled double-
stranded oligonucleotides were purified using mini Quick Spin Oligo Columns (Roche 
Diagnostics, Mannheim, Germany). DNA-protein binding reactions were performed in a 10-
µL mixture containing 5 µg nuclear protein and 1 µg poly(dI-dC) (Sigma-Aldrich) in 4% 
glycerol, 1 mM MgCl2, 0.5 mM EDTA, 0.5 mM dithiothreitol, 50 mM NaCl, 10 mM Tris-
HCl (pH 7.5). Nuclear extracts were incubated with 1 µL 32P-labeled oligonucleotide probe 
(10,000 cpm) at room temperature for 20 minutes and then loaded on a 5% polyacrylamide 
gel (37:5:1). Electrophoresis was performed in 0.5x TBE for 2 hours at 130 V, and the gel 
was visualized by autoradiography. For antibody supershift experiments, nuclear extracts 
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were incubated with 2 µL of antibody for 1 h on ice before the addition of 32P- labeled DNA 
probe. After the addition of labeled DNA probe, the binding reaction was incubated for an 
additional 20 min at room temperature. The antibodies used were ZEB1-1 (H102, 
sc-25388x), ZEB1-2 (C-20, sc-10570x), ZEB1-3 (E-20, sc-10572x), ZEB1-4 (R-17, 
sc-10573x), ZEB2 (SIP1, E-11, sc-271984), and MZF1 (H-45, sc-66991x) from Santa Cruz 
Biotechnology, Inc. (Dallas, TX, USA), and Myc (9E11; Abcam, Cambridge, MA, USA).
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Figure 1. 
Identification of a poorly expressed KIR2DL1 allele. ( a ) qRT-PCR performed on NK cell 
RNA from a NMDP donor. ( b ) KIR gene content typing for this individual. ( c ) FACS 
analysis performed with a KIR2DL1-specific antibody on donor PBMC in the left panel, and 
PBMC from the corresponding hematopoietic transplant recipient in the right panel, 
demonstrating an identical pattern of KIR2DL1 expression in reconstituting donor cells.
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Figure 2. 
A non-transcribed KIR2DL1 allele is generated by recombination between KIR2DL1*004 
and KIR3DP1. The sequence of the region from -1353 to -1093 relative to the translational 
start of the KIR2DL1*004 gene (2DL1*004) is shown, and only nucleotide differences are 
shown for the novel KIR2DL1 allele (2DL1-new) and the non-transcribed KIR3DP1 gene 
(3DP1). The KIR3DP1-derived region of the novel KIR2DL1 allele is shown in bold, and the 
underlined flanking sequences indicate the regions where recombination may have occurred 
to generate the novel KIR2DL1 allele. The boxed sequences represent the consensus ZEB1 
binding half sites in opposing orientations, followed by a Myc/USF site previously shown to 
play a role in distal promoter activity. The upstream ZEB1 site is created in the 2DL1-new 
and 3DP1 sequences due to the A to G SNP.
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Figure 3. 
The KIR2DL1 SNP creates a ZEB-1 binding site. An oligonucleotide probe containing the 
wild-type (wt) or mutant (mut) distal promoter region was combined with nuclear extract 
from YT cells. The left panel shows the appearance of a novel band associated with the 
mutant SNP. The right panel shows the ability of several commercial anti-ZEB antibodies 
(ZEB1-1 to ZEB1-4, ZEB2), together with anti-C-Myc or MZF-1 controls to inhibit 
formation of the novel complex.
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Figure 4. 
The KIR2DL1 SNP is associated with weak expression. Donors were screened by PCR with 
primers specific for the ZEB1 SNP. The upper panel shows three donors with 0, 1, or 2 
copies of the wild type KIR2DL1 gene (WT 2DL1) stained with an NK marker (CD56) on 
the horizontal axis, and a KIR2DL1-specific antibody on the vertical axis. The number 
shown in the upper right quadrant represents the percentage of NK cells reacting with the 
143211 anti-KIR2DL1 antibody. The lower panel shows three donors found to possess the 
ZEB1 SNP. Lack of expression is evident in the individual containing only a mutant 
KIR2DL1 gene (1 copy mut 2DL1). The presence of either KIR2DS5 or KIR2DS3 genes in 
two of the donors is also indicated, as these KIR gene products have been shown to react 
with the 143211 anti-KIR2DL1 antibody23.
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Figure 5. 
The KIR2DL1 SNP is associated with decreased distal transcript expression. Purified NK 
cell RNA from purified donor NK cells was subjected to qRT-PCR with KIR2DL1-specific 
primers detecting distal (a) or proximal (b) transcripts. Expression relative to actin is shown 
on the Y-axis, and KIR2DL1/KIR2DS1 genotype of individual donors is listed on the x-axis. 
Donors were: lacking both KIR2DL1/KIR2DS1 (negative); two copies of wild-type 
KIR2DL1 (2Wt); one copy of Wt KIR2DL1 (1Wt); one Wt, one ZEB1-mutant KIR2DL1 
copy (Wt/Mut); one copy of a mutated KIR2DL1 (1 Mut); and one copy of mutated 
KIR2DL1 and one copy of KIR2DS1 (Mut/2DS1). (c) Transcription start sites (TSS) mapped 
by 5’ RACE are shown for the 365 bp region immediately 5’ of the KIR2DL1 start codon ( 
ATG). TSS are indicated by an asterisk. The underlined sequences represent forward PCR 
primers used for the detection of distal and proximal transcripts in a and b .
Wright et al. Page 16
Genes Immun. Author manuscript; available in PMC 2015 April 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 6. 
KIR2DL1 proximal promoter transcripts contain additional exons that disrupt the KIR2DL1 
open reading frame. (a) A schematic of the KIR2DL1 gene structure is shown. Numbered 
rectangles represent KIR2DL1-coding exons with the start codon in exon 1 labeled ‘ATG’, 
whereas the shaded rectangles marked ‘A’ and ‘B’, represent alternative exons containing 
stop codons indicated by ‘TGA’. Intermediate and proximal transcript initiation sites are 
marked by vertical lines with arrows attached. Lines below the KIR2DL1 gene diagram 
represent cDNA clones isolated from purified NK cell RNA obtained from an individual 
with a single copy of the KIR2DL1 gene containing the ZEB1 SNP. Three distinct isoforms 
of the KIR2DL1 proximal transcript were identified (Prox1-3), each containing different 
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combinations of the alternative exons. (b) The nucleotide sequence of the Prox1 transcript is 
shown, with the KIR2DL1 open reading frame indicated by the amino acid sequence listed 
above. Exon boundaries are marked by vertical lines, and each exon is defined by labeled 
brackets. The stop codons in alternative exons A and B (Alt-exon A/B) are underlined in 
bold. (c) qRT-PCR of alternative exon-containing transcripts using either a distal (2DL1-
Distal-Alt-Exon) or proximal (2DL1-proximal-Alt-Exon) KIR2DL1 forward primer together 
with an alternate exon B reverse primer. Expression relative to actin is shown on the Y-axis, 
and KIR2DL1/KIR2DS1 genotype of individual donors is listed on the x-axis as described 
in Figure 5b.
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Figure 7. 
Three promoters define distinct stages of KIR activation. Schematic of the 5’ control region 
and first 3 KIR-coding exons representing three phases of KIR gene transcription 
(Activation phase; Probabilistic phase; Expression phase) are shown. Promoters are 
indicated by filled rectangles, and light green rectangles highlight promoters that define the 
proposed phases of expression. The site of initiation of KIR protein translation is indicated 
by a vertical line labeled “ATG”, and the location of premature stop codons in alternative 
exons found in forward transcripts from Pro-S are indicated by “TGA”. Black lines ending 
in arrows represent sense coding transcripts, the red and green lines indicate antisense and 
sense transcripts from Pro-S respectively. The red and green colored boxes indicate the 
proposed effects of the antisense and sense transcripts on gene activity.
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